Enanta Pharmaceuticals Inc., of Watertown, Mass., said new data from North Chicago-based Abbvie Inc.'s phase III Gift-I study, its all-oral, interferon- and ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, were presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan.